Vismodegib CAS 879085-55-9

Deskrizzjoni tal-prodott:

Isem tal-Prodott:Vismodegib CAS 879085-55-9

 

Sinonimi:

2-Kloro-N-[4-kloro-3-({2-piridinil)fenil]-4-(metilsulfonil)benzamide;BROMO-1-NAPHTA

BenzaMide, 2-kloro-N-[4-kloro-3-({2-piridinil)fenil]-4-(Methylsulfonyl)-;

VisModegib (GDC-0449);

 

Proprjetajiet Kimiċi u Fiżiċi

Dehra: Abjad għal Off-White Solid

Assaġġ: 99% +

Punt tat-togħlija:561.6±50.0 grad

Punt tat-tidwib:179-181 grad

Piż Molekulari: 421.3

Densità: 1.440

Pka:10.72±0.70

Stabbiltà: Stabbli għal sentejn mid-data tax-xiri kif fornut. Soluzzjonijiet f'DMSO jew etanol jistgħu jinħażnu fi grad -20 sa 3 xhur.

 

Applikazzjoni:

Vimodej targets SMO protein and inhibits Gli activation, thereby inhibiting downstream gene transcription and expression.For the treatment of locally progressive or metastatic basal cell carcinoma in adults who have recurred after surgery or are not well treated with surgery or radiotherapy; One of the most common skin cancers is basal cell carcinoma (BCC), which originates in the surface layer of the skin and does not cause pain to patients. The risk was greatest for skin diseases that were regularly exposed to the sun or ultraviolet light. The development and listing of Vimedji has brought good news to patients with BCC, and its clinical role is important and the target market is huge, and it has to grow into a "giant bomb" class (>$1 biljun) droga fil-futur.

 

 

 

Jekk inti interessat fil-prodotti tagħna jew għandek xi mistoqsijiet, jekk jogħġbok tħossok liberu li tikkuntattjana!

 

 

Prodotti taħt privattiva huma offruti għal skopijiet ta 'R & Ż biss. Madankollu, ir-responsabbiltà finali hija esklussivament tax-xerrej.

It-tags Popolari: vismodegib cas 879085-55-9, manifatturi, fornituri, fabbrika, jixtru, fl-istokk

• Par ta ' l-: Tricine CAS 5704-04-1
• Li jmiss: Trametinib CAS 871700-17-3